Pacira BioSciences Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 829

Employees

  • Stock Symbol
  • PCRX

Stock Symbol

  • Investments
  • 14

  • Share Price
  • $36.47
  • (As of Friday Closing)

Pacira BioSciences General Information

Description

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Contact Information

Website
www.pacira.com
Formerly Known As
Pacira Pharmaceuticals, Blue Acquisition, Pacira
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 5401 West Kennedy Boulevard, Lincoln Center
  • Suite 890
  • Tampa, FL 33609
  • United States
+1 (813)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 5401 West Kennedy Boulevard, Lincoln Center
  • Suite 890
  • Tampa, FL 33609
  • United States
+1 (813)

Pacira BioSciences Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pacira BioSciences Stock Performance

As of 13-Nov-2026, Pacira BioSciences’s stock price is $36.47. Its current market cap is $1.46B with 39.9M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$36.47 $36.46 $18.80 - $36.66 $1.46B 39.9M 1.29M $0.94

Pacira BioSciences Financials Summary

As of 30-Sep-2026, Pacira BioSciences has a trailing 12-month revenue of $743M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,159,626 1,292,365 1,060,517 1,921,916
Revenue 743,301 726,411 700,966 674,978
EBITDA 123,528 99,771 9,429 143,141
Net Income 37,727 7,034 (99,560) 41,955
Total Assets 1,202,639 1,264,917 1,553,516 1,574,386
Total Debt 340,280 418,204 638,853 586,044
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pacira BioSciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pacira BioSciences‘s full profile, request access.

Request a free trial

Pacira BioSciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Pacira BioSciences‘s full profile, request access.

Request a free trial

Pacira BioSciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advanc
Pharmaceuticals
Tampa, FL
829 As of 2025

Miami, FL
 

Vienna, Austria
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pacira BioSciences Competitors (23)

One of Pacira BioSciences’s 23 competitors is Noven Pharmaceuticals, a Corporate Backed or Acquired company based in Miami, FL.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Noven Pharmaceuticals Corporate Backed or Acquired Miami, FL
Pfizer (Vienna) Corporation Vienna, Austria
Pfizer Pakistan Corporation Karachi, Pakistan
Audion Therapeutics Venture Capital-Backed Amsterdam, Netherlands
Gilead Formerly VC-backed Foster City, CA
You’re viewing 5 of 23 competitors. Get the full list »

Pacira BioSciences Patents

Pacira BioSciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025208569-A1 Manufacturing of bupivacaine multivesicular liposomes Pending 20-May-2024
EP-4673147-A1 Manufacturing of bupivacaine multivesicular liposomes Pending 20-May-2024
GB-2644950-A Manufacturing of bupivacaine multivesicular liposomes Pending 20-May-2024
GB-2644950-A8 Manufacturing of bupivacaine multivesicular liposomes Pending 20-May-2024
US-12156940-B1 Manufacturing of bupivacaine multivesicular liposomes Active 20-May-2024 A61K31/445
To view Pacira BioSciences’s complete patent history, request access »

Pacira BioSciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pacira BioSciences Investments & Acquisitions (14)

Pacira BioSciences’s most recent deal was a Merger/Acquisition with GQ Bio Therapeutics for . The deal was made on 27-Feb-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
GQ Bio Therapeutics 27-Feb-2025 Merger/Acquisition Drug Discovery
Kineta (Certain Assets in Seattle, Washington) 10-Feb-2025 Corporate Asset Purchase Buildings and Property
Spine BioPharma 11-Oct-2023 Later Stage VC Drug Discovery
CarthroniX 22-Apr-2022 Later Stage VC Drug Discovery
Genascence 07-Jan-2022 Later Stage VC Biotechnology
You’re viewing 5 of 14 investments and acquisitions. Get the full list »

Pacira BioSciences ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

23.63 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Pacira BioSciences’s complete esg history, request access »

Pacira BioSciences Exits (4)

Pacira BioSciences’s most recent exit was on 02-Dec-2021 from Coda Biotherapeutics. The exit was categorized as with 3 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Coda Biotherapeutics 02-Dec-2021 Completed
  • 3 buyers
Iovera 09-Apr-2019 Completed
TELA Bio 25-Oct-2017 Completed
TELA Bio 27-Jan-2017 Early Stage VC Completed
  • 5 buyers
To view Pacira BioSciences’s complete exits history, request access »

Pacira BioSciences Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
GQ Bio Therapeutics Hamburg, Germany 2012

Pacira BioSciences FAQs

  • When was Pacira BioSciences founded?

    Pacira BioSciences was founded in 2006.

  • Where is Pacira BioSciences headquartered?

    Pacira BioSciences is headquartered in Tampa, FL.

  • What is the size of Pacira BioSciences?

    Pacira BioSciences has 829 total employees.

  • What industry is Pacira BioSciences in?

    Pacira BioSciences’s primary industry is Pharmaceuticals.

  • Is Pacira BioSciences a private or public company?

    Pacira BioSciences is a Public company.

  • What is Pacira BioSciences’s stock symbol?

    The ticker symbol for Pacira BioSciences is PCRX.

  • What is the current stock price of Pacira BioSciences?

    As of 13-Nov-2026 the stock price of Pacira BioSciences is $36.47.

  • What is the current market cap of Pacira BioSciences?

    The current market capitalization of Pacira BioSciences is $1.46B.

  • What is Pacira BioSciences’s current revenue?

    The trailing twelve month revenue for Pacira BioSciences is $743M.

  • Who are Pacira BioSciences’s competitors?

    Noven Pharmaceuticals, Pfizer (Vienna), Pfizer Pakistan, Audion Therapeutics, and Gilead are some of the 23 competitors of Pacira BioSciences.

  • What is Pacira BioSciences’s annual earnings per share (EPS)?

    Pacira BioSciences’s EPS for 12 months was $0.94.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process